Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 4591 AL 4605

Exploring the potential role of rab5 protein in endo-lysosomal impairment in Alzheimer's disease

Behl T, Kaur D, Sehgal A, Singh S, Makeen HA, Albratty M, Abdellatif AAH, Dachani SR, Bungau S.

Biomed Pharmacother. 2022 Apr;148:112773. doi: 10.1016/j.biopha.2022.112773. Epub 2022 Mar 1.

Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimer's disease-associated genes: DTNB and DLG2

Prokopenko D, Lee S, Hecker J, Mullin K, Morgan S, Katsumata Y; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Weiner MW, Fardo DW, Laird N, Bertram L, Hide W, Lange C, Tanzi RE.

Mol Psychiatry. 2022 Apr;27(4):1963-1969. doi: 10.1038/s41380-022-01475-0. Epub 2022 Mar 4.

Alzheimer's disease - the journey of a healthy brain into organ failure

Golde TE.

Mol Neurodegener. 2022 Mar 5;17(1):18. doi: 10.1186/s13024-022-00523-1.

Aerobic Training and Circulating Neurotrophins in Alzheimer's Disease Patients: A Controlled Trial

Stein AM, Coelho FGM, Vital-Silva TM, Rueda AV, Pereira JR, Deslandes AC, Camarini R, Santos Galduróz RF.

Exp Aging Res. 2023 Jan-Feb;49(1):1-17. doi: 10.1080/0361073X.2022.2048586. Epub 2022 Mar 6.

Influence of the Microbiota-Gut-Brain Axis on Cognition in Alzheimer's Disease

Escobar YH, O'Piela D, Wold LE, Mackos AR.

J Alzheimers Dis. 2022;87(1):17-31. doi: 10.3233/JAD-215290.

Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy

Xi Y, Chen Y, Jin Y, Han G, Song M, Song T, Shi Y, Tao L, Huang Z, Zhou J, Ding Y, Zhang H.

J Control Release. 2022 May;345:38-61. doi: 10.1016/j.jconrel.2022.02.034. Epub 2022 Mar 4.

Towards a coherent view of network hyperexcitability in Alzheimer's disease

Lam AD, Shafi MM.

Brain. 2022 Apr 18;145(2):423-425. doi: 10.1093/brain/awac033.

Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression

Wen J, Fu CHY, Tosun D, Veturi Y, Yang Z, Abdulkadir A, Mamourian E, Srinivasan D, Skampardoni I, Singh A, Nawani H, Bao J, Erus G, Shou H, Habes M, Doshi J, Varol E, Mackin RS, Sotiras A, Fan Y, Saykin AJ, Sheline YI, Shen L, Ritchie MD, Wolk DA, Albert M, Resnick SM, Davatzikos C; iSTAGING consortium, ADNI, BIOCARD, and BLSA.

JAMA Psychiatry. 2022 May 1;79(5):464-474. doi: 10.1001/jamapsychiatry.2022.0020.

Whole-genome sequencing reveals novel ethnicity-specific rare variants associated with Alzheimer's disease

Shigemizu D, Asanomi Y, Akiyama S, Mitsumori R, Niida S, Ozaki K.

Mol Psychiatry. 2022 May;27(5):2554-2562. doi: 10.1038/s41380-022-01483-0. Epub 2022 Mar 10.

Simultaneous binding of heme and Cu with amyloid β peptides: active site and reactivities

Nath AK, Dey SG.

Dalton Trans. 2022 Mar 29;51(13):4986-4999. doi: 10.1039/d2dt00162d.

Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes

Michailidis M, Moraitou D, Tata DA, Kalinderi K, Papamitsou T, Papaliagkas V.

Int J Mol Sci. 2022 Feb 28;23(5):2687. doi: 10.3390/ijms23052687.

Tauopathies: The Role of Tau in Cellular Crosstalk and Synaptic Dysfunctions

Caamaño-Moreno M, Gargini R.

Neuroscience. 2023 May 10;518:38-53. doi: 10.1016/j.neuroscience.2022.02.034. Epub 2022 Mar 7.

Central Executive Network and Executive Function in Patients With Alzheimer's Disease and Healthy Individuals: Meta-Analysis of Structural and Functional MRI

Daigle KM, Pietrzykowski MO, Waters AB, Swenson LP, Gansler DA.

J Neuropsychiatry Clin Neurosci. 2022 Summer;34(3):204-213. doi: 10.1176/appi.neuropsych.20110279. Epub 2022 Mar 11.

Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology

Kok FK, van Leerdam SL, de Lange ECM.

J Alzheimers Dis. 2022;87(1):51-81. doi: 10.3233/JAD-210607.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA)

Shim Y, Han HJ, Park KW, Kim BC, Park KH, Park MY, Kim HJ, Moon SY, Choi SH, Park KW, Yang DW, Yoon SJ, Kim SY, Youn YC, Choi H, Yoon KE, Cho HJ, Han SH.

J Alzheimers Dis. 2022;87(1):391-403. doi: 10.3233/JAD-215277.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias